🇺🇸 FDA
Patent

US 10238642

Methods for treating neurogenic orthostatic hypotension

granted A61KA61K31/165A61K31/198

Quick answer

US patent 10238642 (Methods for treating neurogenic orthostatic hypotension) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K31/165, A61K31/198, A61K31/4425, A61K31/4465